Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

At higher stages of disease progression 700mg woul

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153773
(Total Views: 436)
Posted On: 07/09/2024 6:06:13 AM
Posted By: MGK_2
Re: ohm20 #144939
Quote:
At higher stages of disease progression 700mg would have the advantage.



With regards to the NASH trial , one of the greatest problems with it was that baseline level of disease were not acquired for the 700mg dosed arm.

Baseline level of disease was acquired for the 350mg dosed arms.
The 350mg dosed arms were divided into 2 groups. Those who were measured pre-trial to have a corrected T1 (cT1) > 875 but less than 950 and those who were measured pre-trial to have a corrected T1 (cT1) > 950.

This determination of the state of the patient's disease pre-trial was not made in the 700mg treated patients, nor was it made in the Placebo group.

For all we know, the Placebo group could have been filled with very sick patients, full of Stage 7 or 8 disease, and/or Cirrhosis. They also could have been near healthy with Stage 1 or 2 disease without any fibrosis. We really don't know their pre-trial status.

Now, with respect to the 700mg treated patients, I make an argument in Interpretation of NASH Prior to Liver Conference : as to why I believe that about 73% of the 700mg treated patients started off with rather Mild disease. That argument is made under the header, " 700 normal " in the post.

If we knew for sure that many of the 700mg treated patients were as sick as the 350mg treated patients, (actually, we do know that their cT1 > 800 as per trail parameters, but that is far less than the 875 of the 350mg treated patients). As we know, the patients who found the greatest improvement in cT1 were those whose pretrial cT1 was greater than 950. So if we knew this ahead of time, we would be better able to make a head to head comparison.

Therefore, it is imperative that they determine the levels of disease progression prior to initiating leronlimab treatment.



(8)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us